

SPECIALTY QUANTITY LIMIT PROGRAM

CALQUENCE (acalabrutinib)

I. PROGRAM DESCRIPTION

The standard limit is designed to allow a quantity sufficient for the most common uses of the medication. If the member's plan allows a quantity limit exception review for the requested medication, coverage of an additional quantity may be provided up to the exception limit with prior authorization.

II. COVERED QUANTITIES

Medication	Standard Limit	Exception Limit*	FDA-recommended dosing
Calquence (acalabrutinib) 100 mg capsules	60 per 30 days	120 per 30 days	Mantle cell lymphoma, chronic lymphocytic leukemia, and small lymphocytic lymphoma: 100 mg twice daily Administration with strong CYP3A inducer: 200 mg twice daily

*Coverage up to the exception limits may be provided with prior authorization via the Specialty Post Limit Quantity Exception Criteria for approval.

III. REFERENCES

1. Calquence [package insert]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; November 2019.